cardiovascular-agents has been researched along with Movement-Disorders* in 7 studies
1 review(s) available for cardiovascular-agents and Movement-Disorders
Article | Year |
---|---|
Drug therapies for tardive dyskinesia: part 2.
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs. No drugs are approved by the U.S. Food and Drug Administration for treating TD. A number of drugs appear to have some benefit for its treatment, including branched-chain amino acids, piracetam (Nootropil(®), Nootrop(®), Nootropyl(®)), clonazepam (Klonopin(®)), levetiracetam (Keppra(®)), propranolol (Inderal(®)), and clonidine (Catapres(®)), and they would be clinically reasonable to try. Gabapentin (Neurontin(®) and others) has a good safety profile and would be appropriate to consider, although no controlled trials confirm its efficacy. The efficacy of ginkgo biloba should be balanced against its safety concerns. Essential fatty acids have not been shown to be effective. Antioxidant therapies, including vitamin E, melatonin, and vitamin B₆, could conceivably be used together with other drug therapies for the treatment of TD. Topics: Amino Acids, Branched-Chain; Antioxidants; Cardiovascular Agents; Fatty Acids, Essential; GABA Modulators; Humans; Movement Disorders | 2011 |
6 other study(ies) available for cardiovascular-agents and Movement-Disorders
Article | Year |
---|---|
[Walking disorder as presentation of inferior acute myocardial infarction in an elderly patient].
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Heart Function Tests; Humans; Male; Movement Disorders; Myocardial Infarction; Treatment Outcome; Walking | 2004 |
[The use of a new muscle relaxant in the treatment of dyskinetic children].
Topics: Cardiovascular Agents; Cerebral Palsy; Child; Humans; Infant; Movement Disorders; Muscle Relaxants, Central | 1962 |
Carisoprodol in the treatment of children with motor difficulties due to brain impairment.
Topics: Brain; Cardiovascular Agents; Carisoprodol; Cerebral Palsy; Child; Infant; Movement Disorders; Muscle Relaxants, Central | 1961 |
Clinical evaluation of carisoprodol in handicapped children.
Topics: Cardiovascular Agents; Carisoprodol; Child; Disabled Children; Infant; Movement Disorders; Muscle Relaxants, Central | 1960 |
The rationale of treatment of motor disorders with muscle relaxants.
Topics: Cardiovascular Agents; Humans; Movement Disorders; Muscle Relaxants, Central; Nervous System Diseases | 1960 |
Hydrogenated ergot alkaloids in treatment of intermittent claudication.
Topics: Cardiovascular Agents; Dihydroergotoxine; Ergot Alkaloids; Gait; Humans; Intermittent Claudication; Movement Disorders; Oxytocics | 1953 |